Prosecution Insights
Last updated: April 19, 2026
Application No. 18/275,929

GLOBODERA PALLIDA CONTROL AGENT

Non-Final OA §102
Filed
Aug 04, 2023
Examiner
COUGHLIN, MATTHEW P
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nippon Soda Co., Ltd.
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 5m
To Grant
84%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
702 granted / 984 resolved
+11.3% vs TC avg
Moderate +12% lift
Without
With
+12.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
48 currently pending
Career history
1032
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
24.9%
-15.1% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 984 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-8, 10, 11, 14 and 15 are pending in the application. Claims 1, 2, 4, 7, 8, 14 and 15 are rejected. Claims 3, 5, 6, 10 and 11 are withdrawn from further consideration. Election/Restrictions Applicant's election with traverse of the species of Compound No. 1 from Table 1 to prosecute the invention of Group I, claims 1-8, 11, 14 and 15 in the reply filed on December 12th, 2025 is acknowledged. The traversal is on the ground(s) that the PTO has not established undue burden. This is not found persuasive because burden of search is not a factor under unity of invention practice. The requirement is still deemed proper and is therefore made FINAL. As per MPEP 803.02, the examiner will determine whether the entire scope of the claims is patentable. Applicants' elected species is not allowable. MPEP 803.02 states: Following election, the Markush claim will be examined fully with respect to the elected species and further to the extent necessary to determine patentability. […] If the Markush claim is not allowable, the provisional election will be given effect and examination will be limited to the Markush claim and claims to the elected species, with claims drawn to species patentably distinct from the elected species held withdrawn from further consideration. […] If on examination the elected species is found to be anticipated or rendered obvious by prior art, the Markush claim and claims to the elected species will be rejected, and claims to the nonelected species will be held withdrawn from further consideration. As the elected species has been found not allowable, the Markush-type claims have been rejected and claims to the nonelected invention held withdrawn from further consideration. Claims 1, 2, 4, 7, 8, 14 and 15 appear to embrace the elected species and are therefore under examination. Claims 1, 2, 4, 7, 8, 14 and 15 have been examined to the extent that they are readable on the elected embodiment. Since the elected species is not allowable, subject matter not embraced by the elected embodiment is therefore withdrawn from further consideration. Claims 3, 5, 6, 10 and 11 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species or invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on December 12th, 2025. Priority This application is a 35 U.S.C. 371 National Stage Filing of International Application No. PCT/JP2022/002998, filed January 27th, 2022, which claims priority under 35 U.S.C. 119(a-d) to JP2021-027228, filed February 24th, 2021. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file. Information Disclosure Statement The Examiner has considered the Information Disclosure Statement(s) filed on March 31st, 2025 and August 4th, 2023. Improper Markush Grouping The nonstatutory Markush grouping rejection is based on a judicially approved “improper Markush grouping” doctrine. A Markush claim contains an “improper Markush grouping” if: (1) The species of the Markush group do not share a “single structural similarity,” or (2) the species do not share a common use. Members of a Markush group share a “single structural similarity” when they belong to the same recognized physical or chemical class or to the same art-recognized class. Members of a Markush group share a common use when they are disclosed in the specification or known in the art to be functionally equivalent. When an examiner determines that the species of a Markush group do not share a single structural similarity or do not share a common use, then a rejection on the basis that the claim contains an “improper Markush grouping” is appropriate. See the Federal Register, Vol. 76, No. 27, dated February 9, 2011, page 7166. Claims 1, 2, 4, 7, 8, 14 and 15 are rejected under improper Markush grouping as the claims contain an improper grouping of alternatively useable species. In the present case, at least (1) applies. It cannot be said that all members of the Markush group have a single structural similarity. The structures embraced by the permutations of -Y-X- encompass varying heterocyclic structures not recognized as belonging to the same physical or chemical class. For example, in the CPC classification system: compounds containing a 5 or 6-membered non-heteroatom containing ring (corresponding to structures where the partial structure -X-Y- is *-(CH2)-C(=X1)-**) are classified in C07C including C07C 49/537; compounds containing a 5 or 6-membered oxygen containing heterocycle (corresponding to structures where the partial structure -X-Y- is *-O-(C=X1)-**) are classified in various locations including C07D 307/33. compounds containing a 5 or 6-membered sulfur containing heterocycle (corresponding to structures where the partial structure -X-Y- is *-S-(C=X1)-**) are classified in various locations including C07D 333/32. compounds containing a 5 or 6-membered nitrogen containing heterocycle (corresponding to structures where the partial structure -X-Y- is *-N(Rb)-(C=X1)-**) are classified in various locations including C07D 207/267; compounds containing a 5 or 6-membered nitrogen and sulfur containing heterocycle (corresponding to structures where the partial structure -X-Y- is *-NH-SO2-**) are classified in various locations including C07D 275/02. Therefore, it cannot be said that all members of the Markush group have a single structural similarity with respect to the functional groups present and the claims therefore are considered to contain an “improper Markush grouping”. Each one of the five groups above represents its own proper Markush grouping and the same rationale would apply to claims 14 and 15 where the first three options fall within group (4) and the last option falls within group (5). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 2, 4, 7, 8, 14 and 15 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Black et al. Aust. J. Chem., 1973, 26, 2177-2182. Black et al. teach 5,5-dimethyl-4-phenylpyrrolidin-2-one on page 2181, which corresponds to Applicant’s elected species and is embraced by the variables of formula (I) of claim 1 where Ar is unsubstituted phenyl, each R1 is C1 alkyl, R2 is hydrogen, Z is an unsubstituted methylene group and the partial structure -X-Y- is *-N(Rb)-C(=X1)-** where Rb is hydrogen and X1 is oxygen. These definitions are embraced by instant claims 1, 2, 4, 7 and 8. Regarding the limitation of a “Globodera pallida control agent” in claim 1, this limitation appears to be either an intended use or a recitation of an inherent property of the compound contained in a material. MPEP 2111.02 states: “If the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention’s limitations, then the preamble is not considered a limitation and is of no significance to claim construction. Shoes by Firebug LLC v. Stride Rite Children’s Grp., LLC, 962 F.3d 1362, 2020 USPQ2d 10701 (Fed. Cir. 2020)”. In this situation, the prior art teaches the elected species, which is the component required by the claims. MPEP 2112.01 states: “"Products of identical chemical composition can not have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. Id.” Accordingly, the prior art anticipates the instant claims regardless of prior art recognition of the instantly recited property. The same rationale applies to the limitation of a “hatching factor for Globodera pallida” recited in instant claim 14 and the property recited in instant claim 15. Regarding the scope of claim 14 that the factor comprises any one or more of compounds including “5,5-dimethyl-4-phenyl-2-pyrrolidinone having a specific rotation of (-)…,” the prior art teaches a racemic product that would necessarily contain both the (-) and (+) stereoisomers. Since claim 14 does not require, for instance, that the material or composition as a whole have a specific rotation, a racemic mixture is deemed to anticipate instant claim 14. Applicant does not state which claims embrace the elected species in the remarks dated December 12th, 2025; however, if claim 14 were amended to require that the hatching factor contain only the or contain majority (-) stereoisomer, this claims would no longer embrace the elected species as defined by Applicant since Table 1 depicts (and correlates the structure to a registry entry that is) a racemate. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATTHEW P COUGHLIN whose telephone number is (571)270-1311. The examiner can normally be reached Monday - Friday, 10 am - 6 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW P COUGHLIN/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 04, 2023
Application Filed
Jan 10, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600706
METHOD FOR MANUFACTURING LOW-VISCOSITY HARDENER
2y 5m to grant Granted Apr 14, 2026
Patent 12600708
PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12577236
NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR
2y 5m to grant Granted Mar 17, 2026
Patent 12577220
METHOD FOR MANUFACTURING (2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHANOL
2y 5m to grant Granted Mar 17, 2026
Patent 12559503
ANTHELMINTIC AZA-BENZOTHIOPHENE AND AZA-BENZOFURAN COMPOUNDS
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
84%
With Interview (+12.2%)
2y 5m
Median Time to Grant
Low
PTA Risk
Based on 984 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month